GeoVax Labs and decentralised trial global organisation EmVenio Research have announced a partnership for the deployment of a mobile clinical facility in the US for a Phase II Covid-19 booster vaccine study.
The mobile community clinical research facility will be deployed in Claremont, California, for expanding the ongoing trial of GEO-CM04S1 as a booster vaccine for Covid-19 in healthy subjects.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
GeoVax chairman and CEO David Dodd said: “This unique initiative will extend the reach of our Covid-19 vaccine booster trial by leveraging EmVenio Research’s localised clinical trial model.
“As we continue to advance and explore the potential of GEO-CM04S1 as a more robust and durable Covid-19 booster than currently approved vaccine boosters, this collaboration will help reduce the burden of patient recruitment as it brings clinical research to diverse populations directly in their communities.”
The synthetic, attenuated, modified vaccinia Ankara (sMVA) vector vaccine GEO-CM04S1 expresses the SARS-CoV-2 virus’ spike and nucleocapsid antigens.
It is being investigated in two Phase II clinical trials, and in the latest trial as a Covid-19 booster for patients who have already received a US Food and Drug Administration (FDA)-approved vaccine.
The clinical trial will include 60 healthy participants aged 18 years or above and will specifically assess the immunogenicity and safety profile of two GEO-CM04S1 dose levels as booster shots.
The level of SARS-CoV-2 neutralising antibodies and specific T-cell responses are the immunological responses measured throughout the study.
In March last year, GeoVax Labs selected CATO SMS as the company’s clinical research organisation partner to manage two Phase II clinical trials of GEO-CM04S1.
Decentralised Clinical Trial coverage in Clinical Trials Arena is supported by Huma.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
